J Cancer 2018; 9(18):3334-3342. doi:10.7150/jca.25514
Prognostic Role of MicroRNA-497 In Cancer Patients: A Meta-analysis
1. Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
2. Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
# Equal contributors and co-first authors.
Feng J, Gu X, Liu L, Lu M, Ma X, Cao Y, Jiang R, Wang B, Zhao Q. Prognostic Role of MicroRNA-497 In Cancer Patients: A Meta-analysis. J Cancer 2018; 9(18):3334-3342. doi:10.7150/jca.25514. Available from https://www.jcancer.org/v09p3334.htm
Background: MicroRNA-497(miR-497) has been studied for its irreplaceable role of predicting the prognosis of various cancers, but there has been no systematic study to summarize the data. Consequently, we performed this meta-analysis to reveal the association between the expression level of miR-497 and cancer prognosis systematically.
Materials and Methods: PubMed was searched for appropriate studies and a total of 12 eligible publications with 989 cancer patients were recruited into our analysis to assess the strength of the association. Hazard ratios (HRs) and odds ratios (ORs) were analyzed to finish this work.
Results: The cancer patients who have high expressing level of miR-497 are less possible to have lymph node metastasis (OR = 0.25, 95% CI: 0.16-0.40, P < 0.001) and more likely to have favourable tumor-node-metastasis stage (OR = 0.29, 95% CI: 0.17-0.49, P < 0.001). Also, high miR-497 expression level was notably connected to better overall survival (pooled HR = 0.41, 95% CI: 0.32-0.53, P < 0.001).
Conclusions: High expressing levels of miR-497 might be a potential biomarker which can be used to predict the better prognosis of different cancer types.
Keywords: prognosis, biomarker, microRNA-497, cancer, meta-analysis